These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26218792)

  • 1. Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):109-11. PubMed ID: 26218792
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifaximin for the treatment of irritable bowel syndrome.
    Cremonini F; Lembo A
    Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
    Kane JS; Ford AC
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.
    DuPont HL; Wolf RA; Israel RJ; Pimentel M
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795384
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
    Bruzzese E; Pesce M; Sarnelli G; Guarino A
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
    Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic properties and clinical uses of rifaximin.
    DuPont HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
    Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
    Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?
    Purslow C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):263. PubMed ID: 22816171
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.
    Garey KW; Jiang ZD; Bellard A; Dupont HL
    J Clin Gastroenterol; 2009 Jan; 43(1):91-3. PubMed ID: 18385603
    [No Abstract]   [Full Text] [Related]  

  • 16. Rifaximin for irritable bowel syndrome without constipation.
    Krause R; Zollner-Schwetz I; Valentin T
    N Engl J Med; 2011 Apr; 364(15):1467; author reply 1468. PubMed ID: 21488771
    [No Abstract]   [Full Text] [Related]  

  • 17. Rifaximin (Xifaxan 550) for hepatic encephalopathy.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):87. PubMed ID: 21045761
    [No Abstract]   [Full Text] [Related]  

  • 18. Rifaximin for irritable bowel syndrome without constipation.
    Khazeni N; Perlroth D
    N Engl J Med; 2011 Apr; 364(15):1467-8. PubMed ID: 21488770
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifaximin (Xifaxan) for travelers' diarrhea.
    Med Lett Drugs Ther; 2004 Sep; 46(1191):74-5. PubMed ID: 15365508
    [No Abstract]   [Full Text] [Related]  

  • 20. Rifaximin (Xifaxan) for traveler's diarrhea.
    Keenum AJ; Stockton MD
    Am Fam Physician; 2005 Dec; 72(12):2525-6. PubMed ID: 16370411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.